{"id":60866,"date":"2025-03-03T04:02:24","date_gmt":"2025-03-03T03:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/"},"modified":"2025-03-03T04:02:24","modified_gmt":"2025-03-03T03:02:24","slug":"bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/","title":{"rendered":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Advancing Precision Oncology with AI-Driven Multiomics for Optimized Therapy Selection and Improved Patient Outcomes<\/i><\/p>\n<p>WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbostongene.com%2F&amp;esheet=54217145&amp;newsitemid=20250302977365&amp;lan=en-US&amp;anchor=BostonGene&amp;index=1&amp;md5=0902dfcb96595123e9cb7985f17f7476\" rel=\"nofollow\" shape=\"rect\">BostonGene<\/a>, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsite2.convention.co.jp%2Fjsmo2025%2Fenglish%2F&amp;esheet=54217145&amp;newsitemid=20250302977365&amp;lan=en-US&amp;anchor=22nd+Annual+Meeting+of+the+Japanese+Society+of+Medical+Oncology+%28JSMO2025%29&amp;index=2&amp;md5=21db6068290eeb9b4f831faf14ac5aa7\" rel=\"nofollow\" shape=\"rect\">22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025)<\/a> from March 6\u20138, 2025, in Kobe, Japan. This premier conference is dedicated to advancing precision oncology and fostering collaboration among global oncology experts.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/4\/bostongene-logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/4\/bostongene-logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/21\/bostongene-logo.jpg\"><\/a><\/p>\n<p>\nBostonGene will present research demonstrating how its AI-powered multiomics platform transforms cancer biology understanding and enhances treatment selection by integrating multi-scale, multi-modal data analysis.<\/p>\n<p>\nDuring the event, Nathan Fowler, MD, Chief Medical Officer at BostonGene, will deliver a keynote presentation titled \u201c<!-- no quote --><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsite2.convention.co.jp%2Fjsmo2025%2Fenglish%2Fprogram%2F&amp;esheet=54217145&amp;newsitemid=20250302977365&amp;lan=en-US&amp;anchor=Cutting+Edge+of+Genomic+Medicine+and+Novel+Therapy+in+Hematologic+Malignancies&amp;index=3&amp;md5=3b3cd01e56ae473075619773234f74f0\" rel=\"nofollow\" shape=\"rect\"><i>Cutting Edge of Genomic Medicine and Novel Therapy in Hematologic Malignancies<\/i><\/a>.\u201d Dr Fowler will highlight how BostonGene, in collaboration with renowned clinical partners, leverages multiomics techniques to identify biomarker predictors of treatment success, driving the next evolution of drug development.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThursday, March 6 | 8:30 AM \u2013 10:00 AM JST<\/li>\n<li>\nSymposium 3 &#8211; Room 4<\/li>\n<\/ul>\n<p>\n<b>Oral presentations<\/b><\/p>\n<p>\n<b>Multiomic clustering of cutaneous melanoma patients to reveal survival trends based on tumor immune evasion features:<\/b><\/p>\n<p>\nThe presentation highlights BostonGene\u2019s innovative approach of combining genomic and transcriptomic data to identify tumor immune microenvironment patterns linked to survival in patients with cutaneous melanoma.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSaturday, March 8 | 8:30 AM \u2013 9:30 AM JST<\/li>\n<\/ul>\n<p>\n<b>Unraveling sarcomatoid features in clear cell renal cell carcinoma with RNA-seq:<\/b><\/p>\n<p>\nThis presentation will showcase<b> <\/b>the value of predictive modeling in developing targeted therapy to treat clear cell renal carcinoma, emphasizing BostonGene\u2019s Tumor Portrait<sup>TM<\/sup> test in identifying unique and targetable clinical characteristics in cancer.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSaturday, March 8 | 8:30 AM \u2013 9:30 AM JST<\/li>\n<\/ul>\n<p>\n<b>Poster presentations<\/b><\/p>\n<p>\n<b>Effective immune-based treatment of extraskeletal myxoid chondrosarcoma guided by next-generation gene profiling:<\/b><\/p>\n<p>\nThe presentation demonstrates cases of advanced disease with limited treatment options where BostonGene\u2019s comprehensive genomic profiling guided targeted therapy selection.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThursday, March 6 | 1:05 PM \u2013 1:50 PM JST<\/li>\n<\/ul>\n<p>\n<b>Leveraging mappability and analysis of allele frequencies to mitigate false positive germline variant calling:<\/b><\/p>\n<p>\nThis study describes BostonGene\u2019s advanced bioinformatic approaches to improve the reliability of germline variant detection in next-generation sequencing analysis.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFriday, March 7 | 2:05 PM \u2013 2:50 PM JST<\/li>\n<\/ul>\n<p>\n<b>Evaluating the clinical utility of RNA- and DNA-based comprehensive genomic profiling in patients with advanced cancers<\/b>:<\/p>\n<p>\nThis large prospective research study describes the diagnostic and clinical utility of BostonGene\u2019s comprehensive genomic profiling in patients with advanced malignancies.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFriday, March 7 | 2:05 PM \u2013 2:50 PM JST<\/li>\n<\/ul>\n<p>\n<b>Machine learning (ML)-enabled automation for high-throughput data processing in flow cytometry:<\/b><\/p>\n<p>\nThis study highlights<b> <\/b>BostonGene\u2019s novel machine learning-based cell classification algorithm to significantly reduce turnaround time for analyzing cell populations.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSaturday, March 8 | 1:05 PM \u2013 1:50 PM JST<\/li>\n<\/ul>\n<p>\nFor more information or to schedule a meeting with BostonGene during the event, please contact Zlata Polyakova at <a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x7a;&#x6c;&#x61;&#x74;a&#46;&#112;&#111;&#108;&#121;&#x61;&#x6b;&#x6f;&#x76;&#x61;&#64;b&#111;&#115;&#116;&#111;&#x6e;&#x67;&#x65;&#x6e;&#x65;&#46;co&#109;\" rel=\"nofollow\" shape=\"rect\">&#122;&#x6c;&#97;&#x74;&#97;&#x2e;&#112;&#x6f;&#108;&#x79;&#97;&#x6b;&#111;&#x76;&#97;&#x40;&#98;&#x6f;&#115;&#x74;&#111;&#x6e;&#103;&#x65;&#110;&#x65;&#46;&#x63;o&#x6d;<\/a>.<\/p>\n<p>\n<b>About BostonGene Corporation<\/b><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbostongene.com%2F&amp;esheet=54217145&amp;newsitemid=20250302977365&amp;lan=en-US&amp;anchor=BostonGene&amp;index=4&amp;md5=ec289de09307f48bb9f707c1ec28d6e8\" rel=\"nofollow\" shape=\"rect\">BostonGene<\/a> is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients&#8217; molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbostongene.com%2F&amp;esheet=54217145&amp;newsitemid=20250302977365&amp;lan=en-US&amp;anchor=www.BostonGene.com&amp;index=5&amp;md5=117c7b656f43c2bddadb859d80a80e54\" rel=\"nofollow\" shape=\"rect\">www.BostonGene.com<\/a>.<\/p>\n<p>\n<strong>About BostonGene Japan<\/strong><\/p>\n<p>\nBostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene\u2019s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact:<\/b><\/p>\n<p>\n<b>BostonGene<\/b><br \/>Erin Keleher<br \/>\n<br \/>+1-617-283-2285<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x45;&#114;&#x69;&#110;&#x2e;K&#x65;l&#x65;h&#x65;r&#x40;b&#x6f;s&#116;&#x6f;&#110;&#x67;&#101;&#x6e;&#101;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">Er&#105;&#110;&#x2e;&#x4b;&#x65;&#x6c;eh&#101;&#114;&#x40;&#x62;&#x6f;&#x73;to&#110;&#103;&#101;&#x6e;&#x65;&#x2e;&#x63;om<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Advancing Precision Oncology with AI-Driven Multiomics for Optimized Therapy Selection and Improved Patient Outcomes WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6\u20138, 2025, in Kobe, Japan. This premier conference is &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60866","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Advancing Precision Oncology with AI-Driven Multiomics for Optimized Therapy Selection and Improved Patient Outcomes WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6\u20138, 2025, in Kobe, Japan. This premier conference is ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T03:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology\",\"datePublished\":\"2025-03-03T03:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/\"},\"wordCount\":617,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250302977365\\\/en\\\/821014\\\/22\\\/bostongene-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/\",\"name\":\"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250302977365\\\/en\\\/821014\\\/22\\\/bostongene-logo.jpg\",\"datePublished\":\"2025-03-03T03:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250302977365\\\/en\\\/821014\\\/22\\\/bostongene-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250302977365\\\/en\\\/821014\\\/22\\\/bostongene-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/","og_locale":"en_US","og_type":"article","og_title":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend","og_description":"Advancing Precision Oncology with AI-Driven Multiomics for Optimized Therapy Selection and Improved Patient Outcomes WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6\u20138, 2025, in Kobe, Japan. This premier conference is ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-03T03:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology","datePublished":"2025-03-03T03:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/"},"wordCount":617,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/","url":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/","name":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg","datePublished":"2025-03-03T03:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250302977365\/en\/821014\/22\/bostongene-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bostongene-to-showcase-multi-modal-ai-powered-platform-at-the-22nd-annual-meeting-of-the-japanese-society-of-medical-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BostonGene to Showcase Multi-Modal AI-Powered Platform at the 22nd Annual Meeting of the Japanese Society of Medical Oncology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60866"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60866\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}